Clinical Trial Update: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

The document reports the termination of a Phase 2/3 clinical trial evaluating AVP-786 for the treatment of negative symptoms in schizophrenia, with discussions …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: TERMINATED